Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor We would first like to thank Hatoum et al1 for their contribution to the discussion on identifying improved predictors of the response of comorbidities to bariatric surgery. In their study,1 they determined remission of comorbidities via records of diagnosis and prescription drug fills. They have taken a binary approach in identifying the reduction in treatment. Instead, we believe that a more in-depth analysis of the changes to drug regimens after surgery would have helped to provide a better indication to the reader of the response of comorbidities.
Erridge S, Chidambaram S. Important Limitations in Defining the Benefits of Bariatric Surgery for Patients With Type 2 Diabetes. JAMA Surg. 2016;151(6):588. doi:10.1001/jamasurg.2015.5545